Juvenile ankylosing spondylitis, as a clinical entity, is outlined. A double-blind trial compared Safapryn and Butazolidin, each given for 3 months, for 15 treatment periods in 11 patients. No differences were shown, but the study highlighted the problems of assessing this condition, and some comments are made, hopefully, to guide further investigators in this field.
Get full access to this article
View all access options for this article.
References
1.
AnsellB M (1976) Differing patterns in juvenile chronic polyarthritis. Modem Topics in Rheumatology. Editor HughesG V R. (Camelot Press) 65–72
2.
BurnsJ J, RoseR K, GoodwinS, ReichenthalJ, HerningE C & BrodieB B (1955) The metabolic fate of phenylbutazone (Butazolidin) in man. Journal of Pharmacology and Experimental Therapeutics113, 481
3.
HaslockI, OmarA S & WrightV (1976) The absorption of Safapryn in patients with arthritis. British Journal of Clinical Practice30, 89
4.
LeonardsJ R (1974) Are all aspirins alike? Extracts from RACP Symposium on Pain, Canberra, Australia, 2-4 October 1974, pp 7–13
5.
RitchieD M, BoyleJ A, MclnnesJ M, JasaniM K, DalakosT G, GrievesonP & BuchananW W (1968) Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Quarterly Journal of Medicine, New SeriesXXXVII, 147, 393
6.
ScottP J, AnsellB M & HuskissonE C (1977) Measurement of pain in juvenile chronic polyarthritis. Annals of the Rheumatic Diseases36, 186
